Sawhney Roger 4

What Happened
Roger Sawhney, a director of Actuate Therapeutics, was granted 15,000 derivative shares (reported as an award/acquisition) on 2026-05-21. The filing shows a $0.00 per-share acquisition price (total reported value $0) and identifies the award as a derivative security. This is a grant of equity-based compensation rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-21; Form 4 filed 2026-05-22 (timely, next-day filing).
• Instrument: Derivative award (code A — grant/award/acquisition) of 15,000 shares at $0.00 per share.
• Shares owned after the transaction: not disclosed in the provided filing.
• Footnote: Options will vest in full on the one-year anniversary of the grant date (F1).
• No immediate sale or cashless exercise reported.

Context
This appears to be a routine director equity grant, commonly used to align executives/directors with shareholders. Because it’s a derivative award with a future vesting date, it doesn’t reflect an immediate purchase or sale and should not be interpreted as a contemporaneous market sentiment signal.